Title:
2-HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE
Document Type and Number:
WIPO Patent Application WO/2007/037534
Kind Code:
A1
Abstract:
Disclosed is a compound represented by the formula (I) below, which has a glucokinase-activating effect and is thus useful for treatment of diabetes or obesity, or a pharmaceutically acceptable salt thereof. [In the formula, R1 represents an aryl or the like; R11 represents an aryl or the like; R2 represents a formyl or the like; R3 represents a C1-6 alkyl or the like; R4 represents a hydrogen atom or the like; Z1 represents -O- or the like; Z2 represents -O- or the like; Y1-Y4 respectively represent a carbon atom or a nitrogen atom; ring A represents a heteroaryl group; X represents a carbon atom or the like; m represents an integer of 0-2; and q represents an integer of 0-2.]
More Like This:
Inventors:
TAKAHASHI KEIJI (JP)
OGINO YOSHIO (JP)
NISHIMURA TERUYUKI (JP)
OGINO YOSHIO (JP)
NISHIMURA TERUYUKI (JP)
Application Number:
PCT/JP2006/320010
Publication Date:
April 05, 2007
Filing Date:
September 29, 2006
Export Citation:
Assignee:
BANYU PHARMA CO LTD (JP)
TAKAHASHI KEIJI (JP)
OGINO YOSHIO (JP)
NISHIMURA TERUYUKI (JP)
TAKAHASHI KEIJI (JP)
OGINO YOSHIO (JP)
NISHIMURA TERUYUKI (JP)
International Classes:
C07D401/04; A61K31/4439; A61K31/444; A61K31/506; A61P3/04; A61P3/10; A61P43/00; C07D413/14; C07D471/04
Domestic Patent References:
| WO2004031179A1 | 2004-04-15 | |||
| WO2004076420A1 | 2004-09-10 | |||
| WO2004081001A1 | 2004-09-23 | |||
| WO2002032872A1 | 2002-04-25 | |||
| WO2004031179A1 | 2004-04-15 |
Foreign References:
| US3845770A | 1974-11-05 | |||
| US3916899A | 1975-11-04 | |||
| US3536809A | 1970-10-27 | |||
| US3598123A | 1971-08-10 | |||
| US3630200A | 1971-12-28 | |||
| US4008719A | 1977-02-22 |
Other References:
BAUMAN N. ET AL.: "Indole-2-carboxylic acids, a new class of hypoglycemic compounds", BIOCHEM. PHARMACOL., vol. 18, no. 5, 1969, pages 1241 - 1243, XP003006417
See also references of EP 1935890A4
GARFINKEL D. ET AL.: "Computer modeling identifies glucokinase as glucose sensor of pancreatic beta-cells", AMERICAN JOURNAL PHYSIOLOGY, vol. 247, 1984, pages 527 - 536
GRUPE A. ET AL.: "Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis", CELL, vol. 83, 1995, pages 69 - 78
FERRE T. ET AL.: "Correction of diabetic alterations by glucokinase", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., vol. 93, 1996, pages 7225 - 7230, XP002025198, DOI: doi:10.1073/pnas.93.14.7225
VIONNET N. ET AL.: "Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus", NATURE GENETICS, vol. 356, 1992, pages 721 - 722
GLASER B. ET AL.: "Familial hyperinsulinism caused by an activating glucokinase mutation", NEW ENGLAND JOURNAL MEDICINE, vol. 338, 1998, pages 226 - 230
T. W. GREEN: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS
SYNTHETIC COMMUNICATIONS, vol. 29, no. 13, 1999, pages 2211
DIABETES, vol. 45, 1996, pages 1671 - 1677
CRYSTAL GROWTH & DESIGN, vol. 3, no. 4, 2003, pages 573 - 580
See also references of EP 1935890A4
GARFINKEL D. ET AL.: "Computer modeling identifies glucokinase as glucose sensor of pancreatic beta-cells", AMERICAN JOURNAL PHYSIOLOGY, vol. 247, 1984, pages 527 - 536
GRUPE A. ET AL.: "Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis", CELL, vol. 83, 1995, pages 69 - 78
FERRE T. ET AL.: "Correction of diabetic alterations by glucokinase", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE U.S.A., vol. 93, 1996, pages 7225 - 7230, XP002025198, DOI: doi:10.1073/pnas.93.14.7225
VIONNET N. ET AL.: "Nonsense mutation in the glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus", NATURE GENETICS, vol. 356, 1992, pages 721 - 722
GLASER B. ET AL.: "Familial hyperinsulinism caused by an activating glucokinase mutation", NEW ENGLAND JOURNAL MEDICINE, vol. 338, 1998, pages 226 - 230
T. W. GREEN: "Protective Groups in Organic Synthesis", 1991, JOHN WILEY & SONS
SYNTHETIC COMMUNICATIONS, vol. 29, no. 13, 1999, pages 2211
DIABETES, vol. 45, 1996, pages 1671 - 1677
CRYSTAL GROWTH & DESIGN, vol. 3, no. 4, 2003, pages 573 - 580
Attorney, Agent or Firm:
BANYU PHARMACEUTICAL CO., LTD. (1-13-12 Kudankit, Chiyoda-ku Tokyo 67, JP)
Download PDF: